Cardiac AAV9-S100A1 Gene Therapy Rescues Post-Ischemic Heart Failure in a Preclinical Large Animal Model

S100A1 GENETICALLY TARGETED THERAPY REVERSES DYSFUNCTION OF HUMAN FAILING MYOCARDIUM

(2011) Henriette L. Brinks et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure

(2010) Enrico Vizzardi et al.   AMERICAN JOURNAL OF CARDIOLOGY

Heart Disease and Stroke Statistics—2011 Update

(2010) Véronique L. Roger et al.   CIRCULATION

Ca2+ signaling in mouse cardiomyocytes with ablated S100A1 protein

(2010) K. Gusev et al.   GENERAL PHYSIOLOGY AND BIOPHYSICS

Systolic Heart Failure

(2010) John J.V. McMurray   NEW ENGLAND JOURNAL OF MEDICINE

Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction

(2009) Jean-Francois Desjardins et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Large Animal Models of Heart Failure

(2009) Jennifer A. Dixon et al.   Circulation-Heart Failure

S100A1 in cardiovascular health and disease: Closing the gap between basic science and clinical therapy

(2009) Carolin Kraus et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Heart Failure

(2008) Roger J. Hajjar et al.   JOURNAL OF CARDIAC FAILURE